A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti‐tumor treatments

A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating... INTRODUCTIONProstate cancer is the most common non‐cutaneous malignancy and the second leading cause of cancer‐related death in North American men. Patients diagnosed with localized disease are usually treated with surgery or radiotherapy; however, many of these patients are not cured and may later develop a more advanced recurrent form of the disease. Patients with advanced prostate cancer are primarily treated with hormone ablation therapy. While initially most of these patients respond well to treatment, over time the tumor becomes unresponsive and develops into castration‐resistant prostate cancer (CRPC). Current therapies for patients with CRPC, which include taxol‐based chemotherapy, have only temporary effectiveness. Therefore, other treatments that are more effective against advanced prostate cancer and CRPC are needed.Mouse models are essential for expanding our understanding of prostate cancer initiation, development, and progression. In addition, they are vital for the pre‐clincial development of new treatments for advanced prostate cancer. Current mouse models for prostate cancer consist of genetically engineered transgenic mice and mice bearing xenograft tumors. In genetically engineered mice, many genes that are implicated in cancer initiation, development, and progression are altered and modified to create mouse models that mimic cancer progression observed in humans. The advantage of using transgenic mouse http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

A TRAMP‐derived orthotopic prostate syngeneic (TOPS) cancer model for investigating anti‐tumor treatments

Loading next page...
 
/lp/wiley/a-tramp-derived-orthotopic-prostate-syngeneic-tops-cancer-model-for-UTCkHI0tt4
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23490
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONProstate cancer is the most common non‐cutaneous malignancy and the second leading cause of cancer‐related death in North American men. Patients diagnosed with localized disease are usually treated with surgery or radiotherapy; however, many of these patients are not cured and may later develop a more advanced recurrent form of the disease. Patients with advanced prostate cancer are primarily treated with hormone ablation therapy. While initially most of these patients respond well to treatment, over time the tumor becomes unresponsive and develops into castration‐resistant prostate cancer (CRPC). Current therapies for patients with CRPC, which include taxol‐based chemotherapy, have only temporary effectiveness. Therefore, other treatments that are more effective against advanced prostate cancer and CRPC are needed.Mouse models are essential for expanding our understanding of prostate cancer initiation, development, and progression. In addition, they are vital for the pre‐clincial development of new treatments for advanced prostate cancer. Current mouse models for prostate cancer consist of genetically engineered transgenic mice and mice bearing xenograft tumors. In genetically engineered mice, many genes that are implicated in cancer initiation, development, and progression are altered and modified to create mouse models that mimic cancer progression observed in humans. The advantage of using transgenic mouse

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off